[Meta-analysis of the efficacy between gemcitabine-alone and gemcitabine-based chemotherapy applied in advanced pancreatic cancer].
摘要
OBJECTIVE: To compare the efficacy of gemcitabine (GEM) alone and gemcitabine based combination chemotherapy (GEMCOM) on advanced pancreatic cancer. METHODS: Keywords Phase III, gemcitabine and pancreatic cancer were used to search and collect Phase III-randomized references about gemcitabine and gemcitabine-based combination chemotherapy applied on advanced pancreatic cancer. A references-based meta-analysis was made to compare the efficacy between GEM and GEMCOM. Before that, test for heterogeneity was committed. Fixed effect model was used if the I(2) ≤ 50%, and random effect model was used if not. The evaluating indicators were overall response rate and 1-year survival rate. RESULTS: There were 14 randomized controlled trial (RCT) and 10 RCT enrolled in overall response rate analysis and 1-year survival rate analysis, respectively. Results of meta-analysis showed that, arm GEMCOM's overall response rate and 1-year survival rate were higher than arm GEM's (z = 2.190, P = 0.028 vs. z = 4.400, P = 0.000). The differences were significant. The biases of the results were tested by Egger-test. The tests showed that no bias exists in both of two meta-analysis (t = 0.070, P = 0.946 and t = -0.740, P = 0.483) respectively. CONCLUSION: There is a possibility that the gemcitabine-combination is more effective than the gemcitabine on overall response rate and 1-year survival rate.